調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

The Global Respiratory Inhalers Market 2017-2027

呼吸器用吸入器の世界市場

◆タイトル：The Global Respiratory Inhalers Market 2017-2027
◆商品コード：VGAIN705055
◆調査・発行会社：visiongain
◆発行日：2017年3月
◆ページ数：181
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）

Sigle User	GBP3,499 ⇒換算￥475,864	見積依頼/購入/質問フォーム
Departmental/Five User	GBP3,899 ⇒換算￥530,264	見積依頼/購入/質問フォーム
Site License	GBP4,999 ⇒換算￥679,864	見積依頼/購入/質問フォーム

※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、呼吸器用吸入器の世界市場について調査・分析し、呼吸器用吸入器の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・呼吸器用吸入器の世界市場
　（市場規模予測、市場動向、市場の成長要因・阻害要因など）
・呼吸器用吸入器の世界市場：セグメント別市場分析
・呼吸器用吸入器の世界市場：地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Respiratory Inhalers – our new study reveals trends, R&D progress, and predicted revenues
Where is the Respiratory Inhalers market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 181-page report provides 118 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Respiratory Inhalers market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, 8 Products and 3 indications are also forecasted.

Respiratory Inhalers Market Forecasts to 2027, by Product:
• Metered Dose Inhalers
• Dry Powder Inhalers
- Single-Dose DPIs
- Multi-Dose DPIs
• Nebulizers
- Jet / Compressor Nebulizers
- Ultrasonic Nebulizers
- Vibrating-Mesh Nebulizers

Respiratory Inhalers Market Forecasts to 2027, by Application:
• Asthma
• COPD
• Other Respiratory Diseases

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 12 leading national markets:
• The US
• The EU5 markets
- Germany
- France
- UK
- Italy
- Spain
• Japan
• China
• India
• Russia
• Brazil
• Mexico

The report also includes profiles and forecasts for some of the leading companies in the Respiratory Inhalers device market, with a focus on the Respiratory Inhalers device segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.

Leading companies and the potential for market growth
Overall world revenue for Respiratory Inhalers will surpass $33.2bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing use of Respiratory Inhalers across many types of surgery and increasing ageing population will increase sales to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Respiratory Inhalers Market report helps you
In summary, our 181-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the world Respiratory Inhalers market and 2 different segmentations, with 8 product types and 3 applications – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 12 of the leading national markets – US, Mexico, Brazil, Germany, UK, France, Italy, Spain, Japan, China, India, the Rest of World markets.
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Respiratory Inhalers device market and leading companies. You find data, trends and predictions.

Get our report today The Global Respiratory Inhalers Market 2017-2027: Revenue Prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), by Indication (Asthma and COPD) and Geography. Avoid missing out – get our report now.

【レポートの目次】

1. Report Overview
1.1 Global Respiratory Inhalers Market Overview
1.2 Global Respiratory Inhalers Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.9.1 Primary Research
1.9.2 Secondary Research
1.9.3 Market Evaluation & Forecasting Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain

2. Introduction to Respiratory Disorders and Therapies
2.1 An Introduction to Respiratory Disorders
2.1.1 Classification of Respiratory Disorders
2.1.2 Asthma
2.1.2.1 Trends in Asthma Prevalence
2.1.2.2 Pathophysiology of Asthma
2.1.2.3 Symptoms of Asthma
2.1.2.4 Treatment of Asthma
2.1.2.5 Guidelines for Asthma Treatment
2.1.2.6 Drug Treatments for Asthma
2.1.3 Chronic Obstructive Pulmonary Disease (COPD)
2.1.3.1 Trends in COPD Prevalence
2.1.3.2 Pathophysiology of COPD
2.1.3.3 Symptoms of COPD
2.1.3.4 Treatment of COPD
2.1.3.5 Drug Treatments for COPD
2.1.3.6 Guidelines for COPD Treatment
2.2 Major Drug Classes in the Treatment of Asthma and COPD
2.2.1 Bronchodilators
2.2.1.1 Beta2-Agonists
2.2.1.2 Anticholinergics
2.2.1.3 Anti-Inflammatory Drugs
2.2.1.4 Corticosteroids
2.2.1.5 Leukotriene Receptor Antagonists
2.2.1.6 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.2.1.7 Combination Drugs
2.2.2 Phases of Clinical Trials
2.2.3 Regulation of Medical Devices
2.2.3.1 The US Approval and Regulation System
2.2.3.2 The EU Approval and Regulation System
2.2.3.3 Post-Marketing Surveillance in the EU

3. Respiratory Inhalers: Global Market 2016-2027
3.1 The Global Respiratory Inhalers Market in 2016
3.2 Leading Respiratory Inhaler Products
3.3 Leading Companies in the Respiratory Inhalers Market
3.4 Respiratory Inhalers: Trends and Developments
3.4.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.4.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
3.4.3 Telehealth: A Promising Market Trend
3.4.4 Lifecycle Management Strategies to Counter Patent Expiry
3.4.5 Advanced Inhaler Technologies to Counter Generic Erosion

4. Respiratory Inhalers Market, By Product Type
4.1 Metered Dose Inhalers: Market Overview
4.2 Dry Powder Inhalers: Market Overview
4.2.1 Single-Dose DPIs
4.2.2 Multi-Dose DPIs
4.3 Nebulizers: Market Overview
4.3.1 Jet/Compressor Nebulizers
4.3.2 Ultrasonic Nebulizers
4.3.3 Vibrating-Mesh Nebulizers

5. Respiratory Inhalers Market, by Indication
5.1 Asthma: Market Overview
5.2 COPD: Market Overview
5.3 Other Respiratory Diseases

6. Leading National Markets 2016-2027
6.1 Regional Breakdown of the Global Respiratory Inhalers Market
6.2 World Respiratory Inhalers Market Forecast 2016-2027
6.2.1 How will Regional Market Shares Change to 2027?
6.3 The US Respiratory Inhalers Market 2016-2027
6.3.1 The US Respiratory Inhalers Market Forecast 2016-2027
6.3.2 US Respiratory Inhalers Market: Trends and Developments
6.4 EU5 Respiratory Inhalers Market 2016-2027
6.4.1 German Respiratory Inhalers Market Forecast 2016-2027
6.4.2 French Respiratory Inhalers Market Forecast 2016-2027
6.4.3 UK Respiratory Inhalers Market Forecast 2017-2027
6.4.4 Italian Respiratory Inhalers Market Forecast 2017-2027
6.4.5 Spanish Respiratory Inhalers Market Forecast 2017-2027
6.4.6 EU5 Respiratory Inhalers Market: Trends and Developments
6.4.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
6.4.6.2 France: Social Security Finance Bill 2015
6.4.6.3 UK: Improving Asthma and COPD Patient Outcomes
6.4.6.4 Italy: Austerity Measures Limiting Growth
6.4.6.5 Spain: The Start of Recovery in the Spanish Economy
6.5 Japanese Respiratory Inhalers Market 2016-2027
6.6 BRIC Respiratory Inhalers Market 2016-2027
6.6.1 Chinese Respiratory Inhalers Market Forecast 2016-2027
6.6.2 Indian Respiratory Inhalers Market Forecast 2016-2027
6.6.3 Brazilian Respiratory Inhalers Market Forecast 2016-2027
6.6.4 Russian Respiratory Inhalers Market Forecast 2016-2027
6.7 Mexican Respiratory Inhalers Market Forecast 2016-2027

7. Leading Companies in the Respiratory Inhalers Market
7.1 GlaxoSmithKline (GSK)
7.1.1 GSK: Product Portfolio
7.1.2 GSK: Financial Overview
7.1.3 Recent Developments
7.1.3.1 Japanese Regulatory Approval for Relvar Ellipta
7.1.3.2 FDA Filing of Triple Drug Therapy
7.1.3.3 FDA Approval for Breo Ellipta to Adult Asthma Patients
7.1.3.4 Launch of Combination Drugs
7.1.3.5 GSK Presented Data on Eosinophil Levels and COPD
7.1.3.6 Approval for Arnuity Ellipta
7.1.3.7 Approval for Incruse Ellipta
7.1.3.8 GSK: Products in Development
7.2 AstraZeneca
7.2.1 AstraZeneca: Product Portfolio
7.2.2 AstraZeneca: Financial Overview
7.2.3 Recent Developments
7.2.3.1 FDA Approval for Symbicort in Paediatric Patients
7.2.3.2 Charity-Industry Collaboration
7.2.3.3 FDA approval for Bevespi Aerosphere
7.2.3.4 AstraZeneca Acquired Right to Actavis’ Branded Respiratory Portfolio in US and Canada
7.2.3.5 AstraZeneca Acquired Almirall’s Respiratory Portfolio
7.2.3.6 Takeda Respiratory Portfolio Acquisition
7.2.4 AstraZeneca: Products in Development
7.3 Boehringer Ingelheim
7.3.1 Boehringer Ingelheim: Product Portfolio
7.3.2 Boehringer Ingelheim: Financial Overview
7.3.3 Recent Developments
7.3.3.1 Collaboration with Kaohsiung Medical University
7.3.3.2 Collaboration with Weill Cornell Medicine
7.3.3.3 Collaboration with Qualcomm Incorporated
7.3.3.4 Partnership with Propeller Health
7.3.3.5 FDA Approval for Spiriva Respimat
7.3.3.6 Regulatory Approval for Stiolto Respimat
7.3.3.7 Expansion of Respimat Manufacturing Capacity
7.3.3.8 FDA Approval for Stiverdi Respimat
7.3.4 Boehringer Ingelheim: Respiratory Product Pipeline
7.4 Merck & Co. (Merck)
7.4.1 Merck: Product Portfolio
7.4.2 Merck: Financial Overview
7.4.3 Recent Developments
7.4.4 Merck: Products in Development
7.5 Teva
7.5.1 Teva: Product Portfolio
7.5.2 Teva: Financial Overview
7.5.3 Teva: Recent Developments
7.5.3.1 FDA Approval for RespiClick
7.5.3.2 European Approval for Aerivio Spiromax
7.5.3.3 FDA Approval for ProAir RespiClick (albuterol sulfate)
7.5.3.4 Acquisition of Gecko Health Innovations
7.5.3.5 Partnership with IBM Watson Health
7.5.4 Teva: Products in Development
7.6 Novartis International AG
7.6.1 Novartis: Product Portfolio
7.6.2 Novartis: Financial Overview
7.6.3 Novartis: Recent Developments
7.6.3.1 Partnership with Propeller Health
7.6.3.2 Exclusive License Agreement with Sunovion Pharma
7.6.3.3 Partnership with Qualcomm Incorporated
7.6.3.4 FDA Approval for Utibron Neohaler
7.6.3.5 Novartis Presented Data on Ultibro and Seebri
7.6.3.6 Pfizer Promotes Two Novartis COPD drugs in the UK
7.6.4 Novartis: Products Under Development
7.7 Chiesi Farmaceutici S.p.A.
7.7.1 Chiesi: Product Portfolio
7.7.2 Chiesi: Financial Overview
7.7.3 Chiesi: Recent Developments
7.7.3.1 Regulatory Approval for NEXThaler
7.7.3.2 Chiesi: Products Under Development

8. Qualitative Analysis of Respiratory Inhalers Market
8.1 Market Dynamics
8.1.1 Drivers and Opportunities
8.1.1.1 Growing Burden of Respiratory Diseases
8.1.1.2 Smart Inhalers Provide High Growth Opportunities
8.1.1.3 Triple Drug Therapy for COPD To Offer New Revenue Prospects
8.1.2 Restraints and Challenges
8.1.2.1 Patent Expiry and Generic Competition
8.1.2.2 High Cost Impeding Growth of DPIs In Cost-Sensitive Markets
8.2 Porter’s Five Forces Analysis of the Respiratory Inhalers Market
8.2.1 Rivalry among Competitors [Medium]
8.2.2 Threat of New Entrants [Medium]
8.2.3 Power of Suppliers [Medium]
8.2.4 Power of Buyers [High]
8.2.5 Threat of Substitutes [Low]

9. Conclusions
9.1 Respiratory Inhalers: A Maturing Market
9.2 The Global Respiratory Inhalers Market, 2016 – 2027
9.3 Leading Respiratory Inhalers
9.4 Leading Respiratory Inhaler Companies
9.5 Leading Regional and National Markets
9.6 Global Respiratory Inhalers Market Forecast, 2017-2027
9.7 The Future of Respiratory Inhalers Market

10. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 1.1 Respiratory Inhalers Market Forecast Segmented by National Markets: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 2.1 Classification of Respiratory Diseases
Table 2.2 Clinical Trial Phases
Table 3.1 Top 5 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2016
Table 4.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Product Type, 2016-2027
Table 4.2 World Metered Dose Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
Table 4.4 Types of Marketed Breezhaler Device
Table 4.5 Single-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.6 Multi-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.7 World Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Type, 2016-2027
Table 4.8 World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.9 World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.10 World Vibrating-mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Disease Indication, 2016-2027
Table 5.2 World Asthma Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.3 World COPD Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.4 World Other Diseases Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.1 World Respiratory Inhalers Market: Revenues ($m) and Market Shares (%) by Region, 2016
Table 6.2 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2027
Table 6.3 Market Shares (%) of Leading Regional Respiratory Inhalers Markets, 2016, 2022 and 2027
Table 6.4 US Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.5 EU5 Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027
Table 6.6 German Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.7 French Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.8 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.9 Italian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.10 Spanish Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.11 Japanese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.12 BRIC Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.13 Chinese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.14 Indian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.15 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.16 Russian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.17 Mexican Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.1 GSK: Overview, 2016
Table 7.2 GSK: Respiratory Inhaler Products
Table 7.3 GSK: Major Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%), By Product Type, 2016-2027
Table 7.4 GSK: Respiratory Therapies Pipeline, 2016
Table 7.5 AstraZeneca: Overview, 2016
Table 7.6 AstraZeneca: Respiratory Inhaler Products
Table 7.7 AstraZeneca: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
Table 7.8 AstraZeneca: Respiratory Therapies Pipeline, 2016
Table 7.9 Boehringer Ingelheim: Overview, 2016
Table 7.10 Boehringer Ingelheim: Respiratory Inhaler Products
Table 7.11 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
Table 7.12 Merck: Overview, 2016
Table 7.13 Merck: Respiratory Inhaler Products
Table 7.14 Merck: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
Table 7.15 Teva: Overview, 2016
Table 7.16 Teva: Respiratory Inhaler Products
Table 7.17 Teva: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
Table 7.18 Teva: Respiratory Product Pipeline, 2016
Table 7.19 Novartis: Overview, 2016
Table 7.20 Novartis: Respiratory Inhaler Products
Table 7.21 Novartis: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
Table 7.22 Novartis: Respiratory Product Pipeline, 2016
Table 7.23 Chiesi: Overview, 2016
Table 7.24 Chiesi: Respiratory Inhaler Products
Table 7.25 Chiesi: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
Table 9.1 Top 10 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2016

List of Figures
Figure 1.1 Ageing Population Estimates 2010 - 2050
Figure 1.2: Global Respiratory Inhalers: Market Segmentation
Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016
Figure 2.2 Summary of GOLD Guidance for COPD Treatment
Figure 3.1 World Respiratory Inhalers Market: Market Shares (%) for Major National Markets
Figure 3.2 Top 5 Respiratory Inhalers: Market Shares (%), 2016
Figure 4.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027
Figure 4.2 Metered Dose Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027
Figure 4.4 Single-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.5 Multi-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.6 Jet Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.7 Ultrasonic Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.8 Vibrating-mesh Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Disease Indication, 2016-2027
Figure 5.2 World Asthma Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 5.3 World COPD Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 5.4 World Other Respiratory Diseases Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.1 Respiratory Inhalers Market: Revenues ($m) by Region, 2016
Figure 6.2 World Respiratory Inhalers Market: Market Shares (%) by Region, 2016
Figure 6.3 World Respiratory Inhalers Market Forecast: Revenues ($m) by Region, 2016-2027
Figure 6.4 World Respiratory Inhalers Market: Market Shares (%) by Region, 2016
Figure 6.5 World Respiratory Inhalers Market: Market Shares (%) by Region, 2022
Figure 6.6 World Respiratory Inhalers Market: Market Shares (%) by Region, 2027
Figure 6.7 US Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.8 EU5 Respiratory Inhalers Market Forecast: Revenues ($m) by National Market, 2016-2027
Figure 6.9 German Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.10 French Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.11 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 6.12 Italian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.13 Spanish Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.14 Japanese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.15 BRIC Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.16 Chinese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.17 Indian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.18 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.19 Russian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.20 Mexican Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.1 GSK: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.2 GSK: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.3 GSK: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.4 AstraZeneca: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.5 AstraZeneca: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.6 AstraZeneca: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.7 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.8 Boehringer Ingelheim: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.9 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.10 Merck: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.11 Merck: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.12 Merck: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.13 Teva: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.14 Teva: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.15 Teva: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.16 Novartis: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.17 Novartis: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.18 Novartis: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.19 Chiesi: Foster Inhaler Revenue ($m) and AGR (%), 2016-2027
Figure 8.1 Porter’s Five Forces Analysis of the Respiratory Inhalers Market, 2016-2027
Figure 9.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027

【レポートのキーワード】

呼吸器用吸入器

★調査レポート[呼吸器用吸入器の世界市場] ( The Global Respiratory Inhalers Market 2017-2027 / VGAIN705055) 販売に関する免責事項

[呼吸器用吸入器の世界市場] ( The Global Respiratory Inhalers Market 2017-2027 / VGAIN705055) についてEメールでお問い合わせ

◆関連調査資料◆

世界の喘息及びCOPD（慢性閉塞性肺疾患）治療薬市場
VGAIN4120203 / visiongain / 2014年10月 / 当調査レポートでは、世界の喘息及びCOPD（慢性閉塞性肺疾患）治療薬市場について調査・分析し、イントロダクション、セグメント別市場分析、地域別市場分析、市場環境分析、専門家の見解、主要企業分析データなどをお届けいたします。...Asthma and COPD therapies – new study showing you trends, R&D progress, and predicted revenues Where’s the asthma and COPD therapies market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 335-page report provides 264 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market. Forecasts from 2014-2024 and...

呼吸器診断の世界市場
VGAIN7081171 / visiongain / 2017年6月 / visiongain社が発行した当調査レポートでは、呼吸器診断の世界市場について調査・分析し、呼吸器診断の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。・レポートの概要・イントロダクション・呼吸器診断の世界市場　（市場規模予測、市場動向、市場の成長要因・阻害要因など）・呼吸器診断の世界市場：セグメント別市場分析・呼吸器診断の世界市場：地域別市場分析、市場規模予測・市場環境分析・専門家の見解・主要企業分析...The global respiratory diagnostics market is expected to grow at a CAGR of 7.1% in the first half of the forecast period. The market is expected to grow at a CAGR of 7.4% from 2017-2027. The market is estimated at $5.32bn in 2016 and $8.00bn in 2022. In 2016, The instruments and devices submarket held the largest market share at 57.7%, followed by the assays and reagents submarket at 23.8%. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 197-page report you will...

喘息＆COPDの世界市場2016-2026
VGAIN61125 / visiongain / 2016年10月 / 当調査レポートでは、喘息＆COPDの世界市場について調査・分析し、喘息＆COPDの世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 1. レポート概要 2. 喘息＆COPD治療の概要 3. 喘息＆COPD治療：世界市場2016-2026 4. 気管支拡張薬単剤治療市場2016-2026 5....Visiongain’s comprehensive new 313 page report reveals that the global asthma & COPD market will achieve revenues of $33.2bn in 2016. Are you involved in the asthma & COPD market or intend to be? If so, then you must read this report. It’s vital that you keep your knowledge up to date. You need this report. Market scope: Asthma & COPD are among the most common and debilitating respiratory conditions. Drugs for the treatment of these conditions fall into 3 main categories: Bronchodilator monotherapy, anti-inflammatory drugs and combination drugs. Visiongain assesses how these three submarkets and the 12 largest national...

喘息及びCOPD（慢性閉塞性肺疾患）治療の世界市場予測：気管支拡張薬、抗炎症薬
VGAIN5102610 / visiongain / 2015年10月 / 当調査レポートでは、喘息及びCOPD（慢性閉塞性肺疾患）治療の世界市場について調査・分析し、以下の構成でお届けいたします。・レポートの概要・イントロダクション・喘息及びCOPD（慢性閉塞性肺疾患）治療の世界市場　（市場規模予測、市場の成長要因・阻害要因など）・喘息及びCOPD（慢性閉塞性肺疾患）治療の世界市場：地域別市場分析、市場規模予測・気管支拡張薬市場分析：医薬品別販売予測・抗炎症薬市場分析：医薬品別販売予測・市場環境分析・専門家の見解...Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies What can be expected from the Asthma and COPD Therapies market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there. Our 309-page report provides 260 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much...

消炎剤の世界市場予測
VGAIN7081170 / visiongain / 2017年6月 / visiongain社が発行した当調査レポートでは、消炎剤の世界市場について調査・分析し、消炎剤の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。・レポートの概要・イントロダクション・消炎剤の世界市場　（市場規模予測、市場動向、市場の成長要因・阻害要因など）・消炎剤の世界市場：セグメント別市場分析・消炎剤の世界市場：地域別市場分析、市場規模予測・市場環境分析・専門家の見解・主要企業分析...Anti-Inflammatory Therapeutics – our new study reveals trends, R&D progress, and predicted revenues Where is the Anti-Inflammatory Therapeutics market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our 162-page report provides 108 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results,...

顧みられない熱帯病（NTD）治療の世界市場2017-2027
VGAIN7081119 / visiongain / 2017年9月 / visiongain社が発行した当調査レポートでは、顧みられない熱帯病（NTD）治療の世界市場について調査・分析し、顧みられない熱帯病（NTD）治療の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。・レポートの概要・イントロダクション・顧みられない熱帯病（NTD）治療の世界市場　（市場規模予測、市場動向、市場の成長要因・阻害要因など）・顧みられない熱帯病（NTD）治療の世界市場：セグメント別市場分析・顧みられない熱帯病（NTD）治療の世界市場：地域別市場分析、市場規模予測・市場環境分析・専門家の見解・主要企業分析...The Global Treatment for Neglected Tropical Disease market is expected to grow at a CAGR of 7.3% in the second half of the forecast period. The Global Treatment for Neglected Tropical Disease market reached $1.5bn in 2016, dominated by the treatments for malaria which held 30% share of the market. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 157-page report you will receive 71 tables and 80 figures– all unavailable elsewhere. The 157-page report provides clear detailed insight into the Global Treatment...

エリスロポエチンの世界市場予測
VGAIN705045 / visiongain / 2017年4月 / 当調査レポートでは、エリスロポエチンの世界市場について調査・分析し、エリスロポエチンの世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。・レポートの概要・イントロダクション・エリスロポエチンの世界市場　（市場規模予測、市場動向、市場の成長要因・阻害要因など）・エリスロポエチンの世界市場：セグメント別市場分析・エリスロポエチンの世界市場：地域別市場分析、市場規模予測・市場環境分析・専門家の見解・主要企業分析...The global erythropoietin market is expected to grow at a CAGR of 7.8% in the first half of the forecast period and CAGR of 4.8% in the second half of the forecast period. The market is estimated at $7.9bn in 2016 and $16.5bn in 2027. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 164-page report you will receive 84 tables and 93 figures – all unavailable elsewhere. The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key...

ENTデバイスの世界市場予測
VGAIN705058 / visiongain / 2017年3月 / 当調査レポートでは、ENTデバイスの世界市場について調査・分析し、ENTデバイスの世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。・レポートの概要・イントロダクション・ENTデバイスの世界市場　（市場規模予測、市場動向、市場の成長要因・阻害要因など）・ENTデバイスの世界市場：セグメント別市場分析・ENTデバイスの世界市場：地域別市場分析、市場規模予測・市場環境分析・専門家の見解・主要企業分析...ENT Devices – our new study reveals trends, R&D progress, and predicted revenues Where is the ENT Devices market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our 145-page report provides 129 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results,...

出血性障害治療の世界市場2017-2027
VGAIN7081119 / visiongain / 2017年9月 / visiongain社が発行した当調査レポートでは、出血性障害治療の世界市場について調査・分析し、出血性障害治療の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。・レポートの概要・イントロダクション・出血性障害治療の世界市場　（市場規模予測、市場動向、市場の成長要因・阻害要因など）・出血性障害治療の世界市場：セグメント別市場分析・出血性障害治療の世界市場：地域別市場分析、市場規模予測・市場環境分析・専門家の見解・主要企業分析...Bleeding Disorder Treatment – our new study reveals trends, R&D progress, and predicted revenues Where is the Bleeding Disorder Treatment market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead Our 172-page report provides 153 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See...

脳モニタリング装置の世界市場予測2017-2027：脳波図、CT、MRI、脳磁図
VGAIN702036 / visiongain / 2017年2月 / 当調査レポートでは、脳モニタリング装置の世界市場について調査・分析し、脳モニタリング装置の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。・レポートの概要・イントロダクション・脳モニタリング装置の世界市場　（市場規模予測、市場動向、市場の成長要因・阻害要因など）・脳モニタリング装置の世界市場：セグメント別市場分析・脳モニタリング装置の世界市場：地域別市場分析、市場規模予測・市場環境分析・専門家の見解・主要企業分析...Brain monitoring – our new study reveals trends, R&D progress, and predicted revenues Where is the brain monitoring market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our 155-page report provides 119 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results,...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆